Menu
No results found.
000020
Dongwha Pharm.Co.,Ltd – KRX
Weekly Share Price & Valuation Overview
Market Overview
Open
6550.0000
Close
6530.0000
High
6710.0000
Low
6480.0000
Trend
0.59319
Dongwha Pharm.Co.,Ltd
South Korea
• KRX - Korea Stock Exchange
• 000020
• Currency: KRW
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, dermatological, mouth and tooth, hepatic protectors, nutrients, tonics, topic analgesic, antihistamines, sore throat, and others; quasi drugs; health subsidiary foods; foods and drinks; and cosmetics. The company also exports its products. Dongwha Pharm.Co.,Ltd was founded in 1897 and is headquartered in Seoul, South Korea.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 181.28B
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 273.54B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 471.66B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 214.26B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 29.90B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 17.02K
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.75%
- Shares Outstanding
- 27.72M
- Float Shares
- 18.91M
- Implied Shares Outstanding
- 27.80M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
1.81%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
6.34%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
45.43%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
0.55%
- ROA Return on assets: net income ÷ total assets.
-
0.97%
- ROE Return on equity: net income ÷ shareholder equity.
-
-0.39%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Year-over-year revenue growth.
-
5.70%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-99.10%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-98.90%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.05
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.26
- Total Cash Cash and equivalents.
- KRW 39.65B
- Total Debt Short + long-term interest-bearing debt.
- KRW 103.80B
- Net Debt Total debt − cash (negative = net cash).
- KRW 64.15B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 3.47
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW -15.70B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW -99.31B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-3.33%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-21.05%
- Cash Conversion (OpCF/EBITDA)
- -0.53
Sharemaestro House View
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
68.2%
Insiders
Shares held by company insiders (officers, directors).
37.9%
Institutions
Shares held by institutions (funds, pensions).
2.2%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
0.3%
Net Debt
Total debt − cash (negative = net cash).
KRW 64.15B
13.6% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
24
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 03:46
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.